Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23991053 | 0.86 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1 | |
| SCHEMBL10271243 | 0.79 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1 | |
| SCHEMBL24768136 | 0.77 | L3MBTL1 (0.32) | ALDH1A1L3MBTL1 | |
| SCHEMBL23989515 | 0.76 | ALDH1A1 (0.55) | ALDH1A1 | |
| SCHEMBL25858729 | 0.76 | L3MBTL1 (0.47) | ALDH1A1L3MBTL1 | |
| SCHEMBL23989516 | 0.76 | ALDH1A1 (0.55) | ALDH1A1 | |
| SCHEMBL23991103 | 0.74 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL25744920 | 0.74 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL25419236 | 0.74 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL28160485 | 0.73 | L3MBTL1 (0.36) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | ALDH1A1 164/4885L3MBTL1 2415/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | ALDH1A1 164/4885L3MBTL1 2415/4885 |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | ALDH1A1 164/4885L3MBTL1 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.